<DOC>
	<DOCNO>NCT02607280</DOCNO>
	<brief_summary>Investigate safety efficacy DS-5565 Japanese subject Diabetic Peripheral Neuropathic Pain ( DPNP ) renal impairment Post-Herpetic Neuralgia ( PHN ) renal impairment .</brief_summary>
	<brief_title>DS-5565 Phase III Study Renal Impairment Japanese Subjects</brief_title>
	<detailed_description>The primary objective safety tolerability DS-5565 Japanese subject moderate severe renal impairment .</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Neuralgia , Postherpetic</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<criteria>At screening , creatinine clearance ( use CockcroftGault equation ) : 1559 mL/min At screening , pain scale â‰¥ 40 mm Type 1 type 2 diabetes mellitus screening ( patient diabetic peripheral neuropathic pain DPNP ) . Painful distal symmetric polyneuropathy ( patient DPNP ) postherpetic neuralgia PHN define pain present 3 month herpes zoster skin rash screening ( patient PHN ) HbA1c ( National Glycohemoglobin Standardization Program ) &gt; 10.0 % ( patient DPNP ) Previous use neurolytic block ( patient PHN )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Diabetic peripheral neuropathic pain</keyword>
	<keyword>post-herpetic neuralgia</keyword>
	<keyword>renal impairment</keyword>
</DOC>